Sevelamer

被引：6

作者：

Henderson, J ^{[1
]}

Altmann, P ^{[1
]}

机构：

[1] Oxford Radcliffe Hosp NHS Trust, Churchill Hosp, Oxford Kidney Unit, Oxford OX3 7LJ, England

来源：

NEPHRON CLINICAL PRACTICE | 2003年 / 94卷 / 03期

关键词：

sevelamer; phosphate binders; hyperphosphataemia;

D O I：

10.1159/000072021

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Hyperphosphataemia in patients with chronic renal failure has traditionally been treated with calcium- and aluminium-containing phosphate binders. This article briefly discusses the rationale and complications of these treatments and reviews sevelamer that is a novel non-calcium, non-aluminium-containing phosphate binder and the evidence to support its use in clinical practice. Copyright (C) 2003 S. Karger AG, Basel.

引用

页码：C53 / C58

页数：6

共 20 条

[1] A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients [J].

Bleyer, AJ ;

Burke, SK ;

Dillon, M ;

Garrett, B ;

Kant, KS ;

Lynch, D ;

Rahman, SN ;

Schoenfeld, P ;

Teitelbaum, I ;

Zeig, S ;

Slatopolsky, E .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (04) :694-701

[2] Sevelamer hydrochloride (Renagel®), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics [J].

Burke, S ;

Amin, N ;

Incerti, C ;

Plone, M ;

Watson, N .

JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (02) :193-198

[3] Renagel®:: reducing serum phosphorus in haemodialysis patients [J].

Burke, SK .

HOSPITAL MEDICINE, 2000, 61 (09) :622-627

[4] RenaGel(R), a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers [J].

Burke, SK ;

Slatopolsky, EA ;

Goldberg, DI .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (08) :1640-1644

[5] Sevelamer hydrochloride (Renagel®), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers [J].

Burke, SK ;

Amin, NS ;

Incerti, C ;

Plone, MA ;

Lee, JW .

JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (02) :199-205

[6]

Chertow GM, 1999, CLIN NEPHROL, V51, P18

[7] Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure [J].

Chertow, GM ;

Burke, SK ;

Lazarus, JM ;

Stenzel, KH ;

Wombolt, D ;

Goldberg, D ;

Bonventre, JV ;

Slatopolsky, E .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (01) :66-71

[8] Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J].

Chertow, GM ;

Burke, SK ;

Raggi, P .

KIDNEY INTERNATIONAL, 2002, 62 (01) :245-252

[9]

Collins AJ, 2000, CLIN NEPHROL, V54, P334

[10]

Cozzolino M, 2002, J AM SOC NEPHROL, V13, p579A

← 1 2 →